These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 16075278)

  • 1. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
    Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
    Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
    Raymond E; Buquet-Fagot C; Djelloul S; Mester J; Cvitkovic E; Allain P; Louvet C; Gespach C
    Anticancer Drugs; 1997 Oct; 8(9):876-85. PubMed ID: 9402315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.
    Poindessous V; Koeppel F; Raymond E; Comisso M; Waters SJ; Larsen AK
    Clin Cancer Res; 2003 Jul; 9(7):2817-25. PubMed ID: 12855662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
    van Laar ES; Izbicka E; Weitman S; Medina-Gundrum L; Macdonald JR; Waters SJ
    Int J Gynecol Cancer; 2004; 14(5):824-31. PubMed ID: 15361190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
    Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
    Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.
    Sharp SY; O'Neill CF; Rogers P; Boxall FE; Kelland LR
    Eur J Cancer; 2002 Nov; 38(17):2309-15. PubMed ID: 12441268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells.
    El Khoury F; Corcos L; Durand S; Simon B; Le Jossic-Corcos C
    Int J Oncol; 2016 Dec; 49(6):2558-2568. PubMed ID: 27748801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
    Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells.
    Koeppel F; Poindessous V; Lazar V; Raymond E; Sarasin A; Larsen AK
    Clin Cancer Res; 2004 Aug; 10(16):5604-13. PubMed ID: 15328203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.
    Faivre S; Raymond E; Woynarowski JM; Cvitkovic E
    Cancer Chemother Pharmacol; 1999; 44(2):117-23. PubMed ID: 10412945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells.
    Fujie Y; Yamamoto H; Ngan CY; Takagi A; Hayashi T; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
    Jpn J Clin Oncol; 2005 Aug; 35(8):453-63. PubMed ID: 16024531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells.
    Montopoli M; Ragazzi E; Froldi G; Caparrotta L
    Cell Prolif; 2009 Apr; 42(2):195-206. PubMed ID: 19236381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents.
    Vasilevskaya IA; Selvakumaran M; Hierro LC; Goldstein SR; Winkler JD; O'Dwyer PJ
    Clin Cancer Res; 2015 Sep; 21(18):4143-52. PubMed ID: 26023085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frondoside A Enhances the Anti-Cancer Effects of Oxaliplatin and 5-Fluorouracil on Colon Cancer Cells.
    Attoub S; Arafat K; Khalaf T; Sulaiman S; Iratni R
    Nutrients; 2018 May; 10(5):. PubMed ID: 29724012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irofulven induces apoptosis in breast cancer cells regardless of caspase-3 status.
    Herzig MC; Liang H; Johnson AE; Woynarowska B; Woynarowski JM
    Breast Cancer Res Treat; 2002 Jan; 71(2):133-43. PubMed ID: 11883439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
    Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
    Lin J; Hsiao PW; Chiu TH; Chao JI
    Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.